Innovent Biologics (HKSE:01801) Operating Cash Flow per Share : HK$0.09 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Operating Cash Flow per Share?

Innovent Biologics's operating cash flow per share for the six months ended in Dec. 2023 was HK$0.53. Innovent Biologics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Innovent Biologics's Operating Cash Flow per Share or its related term are showing as below:

During the past 8 years, Innovent Biologics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 20.80% per year. The lowest was -62.90% per year. And the median was 11.35% per year.

HKSE:01801's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Innovent Biologics Operating Cash Flow per Share Historical Data

The historical data trend for Innovent Biologics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Operating Cash Flow per Share Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.57

-0.27

-1.70

-1.44

0.10

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial										-0.85	-0.65	-0.82	-0.44	0.53

Competitive Comparison of Innovent Biologics's Operating Cash Flow per Share

For the Biotechnology subindustry, Innovent Biologics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Price-to-Operating-Cash-Flow falls into.

Innovent Biologics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Innovent Biologics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	161.671	/	1559.637
	=	0.10

Innovent Biologics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	842.976	/	1583.953
	=	0.53

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.09

Innovent Biologics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
Yu De-chao Michael	2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Eight Roads Investments	2101 Beneficial owner
Fullerton Management Pte Ltd	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited	2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd.	2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines